Prometheus Biosciences Inc (RXDX) PT Raised to $55 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts RXDX Hot Sheet
Price: $199.92 --0%
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 18 | New: 18
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 18 | New: 18
Join SI Premium – FREE
Stifel analyst Annabel Samimy raised the price target on Prometheus Biosciences Inc (NASDAQ: RXDX) to $55.00 (from $50.00) while maintaining a Buy rating.
You May Also Be Interested In
- Ayala Corporation (AC:PM) (AYYLF) PT Raised to PHP670 at JPMorgan
- Hindustan Unilever Ltd (HUVR:IN) PT Lowered to INR2,600 at UBS
- GE Vernova (GEV) PT Raised to $1,375 at Oppenheimer, 'We remain constructive'
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
